Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients With Diabetes Mellitus

Diabetes Mellitus Clinical Trial

— TEMD  

Official title:

Turkish Nationwide SurvEy of Glycemic and Other Metabolic Parameters of Patients With Diabetes Mellitus (TEMD Study)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03455101
• Other study ID #: GSM012017
• Status: Completed
• Phase: N/A
• First received: September 24, 2017
• Last updated: February 27, 2018
• Start date: April 1, 2017
• Est. completion date: June 30, 2017

Study information

• Verified date: February 2018
• Source: Gulhane School of Medicine
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This study evaluates the overall cardiovascular risk status and best predictors of optimal metabolic control of Turkish adult patients with diabetes mellitus.

Description:

Diabetes mellitus is one of the most common chronic diseases with an increasing prevalence worldwide.The prevalence of diabetes is also increased significantly in Turkey, from 7.2 % in 2002 to 13.7% in 2012.This increasing prevalence leads to serious public health problems and a significant economic burden. Therefore, the optimal treatment of diabetes and prevention of diabetic complications, especially the cardiovascular outcomes, is utmost important. Although achieving glycemic targets in patients with diabetes is of great importance, blood glucose is not the only predictor of cardiovascular outcome in diabetes. Optimization of other metabolic parameters such as lipids, arterial blood pressure (ABP), and body weight as well as a healthy lifestyle are utmost important. As there is hardly enough data about glycemic and other metabolic control parameters in Turkish adult patients with type 1 or type 2 diabetes, this nationwide survey was performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 5240
• Est. completion date: June 30, 2017
• Est. primary completion date: June 30, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with type 1 or type 2 diabetes

• Upper than 18 years old

• To be under follow-up in the same center for at least one year.

Exclusion Criteria:

• Pregnancy

• Younger than 18 years old,

• History of decompensated liver disease,

• History of psychiatric disorders interfering cognition or compliance

• History of bariatric surgery

• History of renal replacement therapy.

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Other:
• There is no intervention.
There is no intervention.

Locations

Country	Name	City	State
Turkey	Gulhane School of Medicine Department of Endocrinology and Metabolism	Ankara

Sponsors (1)

Lead Sponsor	Collaborator
Gulhane School of Medicine

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glycemia control status of Turkish adult patients with diabetes mellitus	Glycemia control will be defined as good control if the mean HbA1c level of patients < 7% or poor control if the mean HbA1c level of patient > 7%	7 days
Secondary	Blood pressure control status of Turkish adult patients with diabetes mellitus	Home blood pressure <135/85 mmHg will be defined as under control.	7 days
Secondary	Lipid control status of Turkish adult patients with diabetes mellitus.	Triglyceride < 150 mg/dl, LDL-C < 100 mg/dl, HDL-C > 40 mg/dl for men, and HDL-C > 50 mg/dl for women will be defined as under control.	7 days.
Secondary	Weight control status of Turkish adult patients with diabetes mellitus.	Body mass index < 30 kg/m2 will be defined as under control. Weight and height will be combined to report body mass index in kg/m2.	7 days.